Stay updated with breaking news from Ionis Core. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) EVP Patrick R. O’neil sold 1,527 shares of the company’s stock in a transaction dated Wednesday, May 24th. The stock was sold at an average price of $41.70, for a total transaction of $63,675.90. Following the sale, the executive vice president now directly owns 40,355 shares in the […]
Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) have been given a consensus rating of “Hold” by the fourteen research firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and five have assigned a buy recommendation to the […]
StockNews.com started coverage on shares of Ionis Pharmaceuticals (NASDAQ:IONS – Get Rating) in a research report released on Thursday morning. The firm issued a hold rating on the stock. Several other research firms also recently weighed in on IONS. Sanford C. Bernstein initiated coverage on shares of Ionis Pharmaceuticals in a research note on Tuesday, […]
MQS Management LLC acquired a new stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 6,547 shares of the company’s stock, valued at approximately $247,000. A number of other institutional investors and hedge […]
First Trust Advisors LP trimmed its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) by 14.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,780,933 shares of the company’s stock after selling 296,327 shares during the quarter. […]